Title

Polatuzumab Vedotin (Pv) Alone Or In-Combination with Obinutuzumab significantly Enhances In-Vitro/In-Vivo Cytotoxicity Against Burkitt Lymphoma (BL)/primary Mediastinal Large B Cell Lymphoma (PMBL)

Document Type

Abstract

Publication Date

6-2018

Department

Pediatrics

Second Department

Health Behavior and Community Health

This document is currently not available here.

Share

COinS